Bilateral panuveitis associated with letrozole therapy
Brian T. Cheng, Justin C. Muste, Sidra Zafar, Mak B. Djulbegovic, Eric D. Kim, Flavius A. Beca, James P. Dunn, Sunir J. Garg, Jordan D. DeanerPurpose:
Letrozole is a non-steroidal aromatase inhibitor commonly used for the treatment of postmenopausal estrogen receptor-positive breast cancer. We report a novel case of bilateral panuveitis associated with letrozole therapy.
Methods:
Retrospective chart review.
Results:
A 39-year-old female with a history of breast cancer presented with bilateral anterior chamber and vitreous inflammation, perivenular sheathing, retinal hemorrhages, and a focal area of retinal whitening in the left eye six weeks after starting letrozole therapy. Extensive infectious and systemic inflammatory work-up was negative. With letrozole cessation and corticosteroid therapy, the inflammation resolved, and the visual acuity improved to 20/20 bilaterally.
Discussion and Conclusion:
Letrozole-associated panuveitis has not previously been reported. This case highlights the importance of detailed medication history as well as the need for interdisciplinary collaboration when managing drug-induced uveitis. Early recognition and appropriate therapy can result in favorable visual outcomes.